Neuro-oncology advances

Awake craniotomy for resection of supratentorial glioblastoma: a systematic review and meta-analysis.

Neuro-oncology advances

Zhang JJY, Lee KS, Voisin MR, Hervey-Jumper SL, Berger MS, Zadeh G

Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults.

Neuro-oncology advances

Schulte JD, Buerki RA, Lapointe S, Molinaro AM, Zhang Y, Villanueva-Meyer JE, Perry A, Phillips JJ, Tihan T, Bollen AW, Pekmezci M, Butowski N, Oberheim Bush NA, Taylor JW, Chang SM, Theodosopoulos P, Aghi MK, Hervey-Jumper SL, Berger MS, Solomon DA, Clarke JL

Timing of glioblastoma surgery and patient outcomes: a multicenter cohort study.

Neuro-oncology advances

M?ller DMJ, De Swart ME, Ardon H, Barkhof F, Bello L, Berger MS, Bouwknegt W, Van den Brink WA, Conti Nibali M, Eijgelaar RS, Furtner J, Han SJ, Hervey-Jumper S, Idema AJS, Kiesel B, Kloet A, Mandonnet E, Robe PAJT, Rossi M, Sciortino T, Vandertop WP, Visser M, Wagemakers M, Widhalm G, Witte MG, De Witt Hamer PC

ECOA-5. Integrative 3D spatial characterization of genomic and epigenomic intratumoral heterogeneity in glioblastoma.

Neuro-oncology advances

Radhika Mathur, Qixuan Wang, Patrick Schupp, Stephanie Hilz, Chibo Hong, Ivan Smirnov, Marisa Lafontaine, Devika Nair, Sriranga Iyyanaki, Joanna Phillips, Susan Chang, Yan Li, Janine Lupo, Michael Oldham, Feng Yue, Joseph Costello

Mouse models of glioblastoma for the evaluation of novel therapeutic strategies.

Neuro-oncology advances

Haddad AF, Young JS, Amara D, Berger MS, Raleigh DR, Aghi MK, Butowski NA

Generation of immunocompetent syngeneic allograft mouse models for pediatric diffuse midline glioma.

Neuro-oncology advances

du Chatinier A, Meel MH, Das AI, Metselaar DS, Waranecki P, Bugiani M, Breur M, Simonds EF, Lu ED, Weiss WA, Garcia Vallejo JJ, Hoving EW, Phoenix TN, Hulleman E

TERT promotor status does not add prognostic information in IDH-wildtype glioblastomas fulfilling other diagnostic WHO criteria: A report of the RANO resect group.

Neuro-oncology advances

Karschnia P, Young JS, Dono A, Häni L, Juenger ST, Sciortino T, Bruno F, Teske N, Morshed RA, Haddad AF, Zhang Y, Stoecklein S, Vogelbaum MA, Beck J, Tandon N, Hervey-Jumper S, Molinaro AM, Rudà R, Bello L, Schnell O, Esquenazi Y, Ruge MI, Grau SJ, van den Bent M, Weller M, Berger MS, Chang SM, Tonn JC

CDKN2A/B co-deletion is associated with increased risk of local and distant intracranial recurrence after surgical resection of brain metastases.

Neuro-oncology advances

Morshed RA, Nguyen MP, Cummins DD, Saggi S, Young JS, Haddad AF, Goldschmidt E, Chang EF, McDermott MW, Berger MS, Theodosopoulos PV, Hervey-Jumper SL, Daras M, Aghi MK

Quantitative analysis of MGMT promoter methylation in glioblastoma suggests nonlinear prognostic effect.

Neuro-oncology advances

Gibson D, Ravi A, Rodriguez E, Chang S, Oberheim Bush N, Taylor J, Clarke J, Solomon D, Scheffler A, Witte J, Lambing H, Okada H, Berger M, Chehab F, Butowski NA

Level I and II deficits-A clinical survey on international practice of awake craniotomy and definitions of postoperative "major" and "minor" deficits.

Neuro-oncology advances

Vooijs M, Robertson FC, Blitz SE, Jungk C, Krieg SM, Schucht P, De Vleeschouwer S, Vincent AJPE, Berger MS, Nahed BV, Broekman MLD, Gerritsen JKW

Pages